News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Common environmentally practices for single-use systems must be adapted before industry “becomes too set in its ways,” says Greenpeace, despite biocontamination currently impeding recycling efforts.
Novartis has spent $20m (€15m) on a centre for T-cell R&D and manufacturing at the University of Pennsylvania.
Baxter International will spin off its biopharmaceutical treatments and manufacturing facilities to form a new company known as Baxalta, which is expected to launch in mid-2015.
Seattle Genetics and Genmab have entered into another antibody-drug conjugate (ADC)partnership under which Genmab will pay $11m upfront for use of Seattle’s auristatin-based ADC technology.